Is Chewy a Buy After Its Latest Earnings Report?

Chewy shares fell 11% after Q2 revenue rose 7.3% to $3.33 billion, only slightly above the $3.32 billion consensus, while adjusted EPS of $0.36 merely matched expectations. Organic revenue growth was just 5.7% excluding SmartPak and Modern Animal, and management cited continued weakness in discretionary attachment purchases and premiumization. Although Chewy raised FY revenue guidance to $13.46 billion-$13.57 billion and EBITDA margin guidance to 6.7%-6.8%, the upgrade was driven primarily by acquisitions rather than improving core demand.

Analysis

CHWY's selloff is less about the quarter and more about a quality-of-growth reset: acquired revenue is masking slower core demand while the highest-margin discretionary basket is under pressure. The expanding Autoship mix stabilizes repeat revenue and reduces churn risk, but it also lowers the addressable pool for incremental, higher-ticket attach purchases; without renewed premiumization, EBITDA-margin upside is likely capped despite scale benefits. The market should increasingly value CHWY against defensive retail and staples multiples rather than e-commerce growth comparables, leaving downside if consensus still assumes a return to high-single-digit organic growth.

The acquisitions may be strategically more valuable than their near-term revenue contribution because they move CHWY toward fragmented specialty verticals and veterinary services, where customer lifetime value and cross-sell data are stronger. The key uncertainty is whether veterinary integration becomes an efficient acquisition channel or simply imports labor-intensive, low-margin service exposure. Over the next 1-3 months, estimate revisions will hinge on organic-sales disclosure, discretionary-category commentary, and whether EBITDA guidance holds after promotions; over 6-18 months, proof of cross-selling from Modern Animal into the core platform is the structural catalyst.

Consensus may be too quick to treat the post-earnings decline as a simple value opportunity. The relevant valuation question is not adjusted EPS but incremental free cash flow after stock compensation and acquisition integration spending; a modest headline P/E can coexist with weak per-share economic earnings. Conversely, a sustained improvement in pet-health attachment would challenge the bear case because it could raise retention and reduce reliance on paid customer acquisition, a mechanism not reflected in core retail growth alone.

Key Decisions for Investors

• Maintain an underweight/short bias on CHWY for the next 1-3 months only if the post-earnings rebound fails below the prior support range; target a further 10-15% downside on organic-growth estimate cuts. Cover if management demonstrates core growth above 7% for two quarters or raises EBITDA-margin guidance above the current range without acquisition-related benefit.
• Express the relative thesis via long PG / short CHWY, sized beta-neutral, over 3-6 months. PG offers more defensible pricing and premiumization resilience, while CHWY remains exposed to discretionary mix; exit if consumer discretionary demand broadens materially or CHWY shows measurable veterinary-led cross-sell traction.
• Do not buy CHWY solely on adjusted valuation. Place a watch alert for disclosed Modern Animal customer economics: evidence of improving clinic-level margins, higher retention, or material core-platform conversion would justify reassessing for a 6-18 month long.
• Monitor pet-category peers and consumer data for a reversal signal: an improving discretionary retail backdrop could lift CHWY sharply given depressed positioning, but the long case requires organic revenue acceleration rather than acquisition-led guidance increases.